CoreWeave (CRWV) Stock Declines Amid Analyst Rating Change

Author's Avatar
Jul 10, 2025

CoreWeave (CRWV, Financial) experienced a significant stock price drop of 9.64% today, trading at $138.29. This decline contrasts with a 0.3% uptick in the S&P 500 and a stable Nasdaq Composite. The price movement is linked to analyst coverage changes, highlighting valuation concerns over the company's planned acquisition of Core Scientific.

Investment firm Needham revised its recommendation for CoreWeave from "buy" to "hold," citing valuation issues. This adjustment follows CoreWeave's announcement of a $9 billion all-stock acquisition of Core Scientific to bolster its AI processing capabilities. Despite the strategic intent, the issuance of new stock to fund the acquisition has led to investor apprehension regarding the company's valuation.

The financial indicators for CoreWeave paint a cautious picture. With a market cap of $66,581.6 million and an enterprise value of $84,308.42 million, the company exhibits a high price-to-book (PB) ratio of 20.95, raising concerns about its valuation given the lack of profitability. CoreWeave's financial strength appears questionable, marked by an Altman Z-Score of 0.98, indicating a distress zone and potential bankruptcy risk over the next two years. Additionally, the interest coverage ratio remains extremely low at 0.21, unable to cover interest expenses, which could necessitate further debt issuance.

On the profitability front, CoreWeave's negative earnings per share (-$1.66) and a net margin of -21.17% further underscore the challenges the company faces in achieving profitable growth. Despite an impressive trailing twelve months sales figure of $1,729.06 million, the company's return on equity (ROE) is deeply negative at -47.5%, reflecting inefficiencies in capital utilization.

While CoreWeave's innovations in cloud infrastructure and AI development are promising, the current financial health and valuation metrics raise concerns. It's crucial for investors to consider these factors carefully, monitoring the outcome of the Core Scientific acquisition closely.

For more insight into CoreWeave's valuation, you can refer to its GF Value.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.